Cefdinir
FDA-approved product (capsule, oral), marketed as Cefdinir, Omnicef.
- Registered studies
- 32
- Lab records
- 8
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Chronic bronchitis
- Infection
- Infectious otitis media
- Otitis media
- Pharyngitis
- Pneumonia
- Recurrent tonsillitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Third-generation cephalosporins
- FDA pharmacologic class
- Cephalosporin Antibacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DD15; FDA class Cephalosporin Antibacterial
Repurposing investigation
Cefdinir is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
32registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
- E. coli: measured active in 4 of 4 lab records
- K. pneumoniae: measured active in 2 of 2 lab records
Show the 8 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefdinir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FlumazenilExisting use: Antidotes43.6% AI-predicted activityagainst E. coli50+ registered studies
- Tenapanor HydrochlorideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome43.6% AI-predicted activityagainst E. coli2 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more43.5% AI-predicted activityagainst E. coli21 registered studies
- Sunitinib MalateExisting use: Cancer, Clear cell renal carcinoma, Gastrointestinal stromal tumor and 6 more43.5% AI-predicted activityagainst E. coli50+ registered studies
- Trazodone HydrochlorideExisting use: Depressive disorder, Major depressive disorder43.5% AI-predicted activityagainst E. coli50+ registered studies
- Donepezil HydrochlorideExisting use: Alzheimer disease, Dementia43.4% AI-predicted activityagainst E. coli50+ registered studies
- EtravirineExisting use: HIV infection, HIV-1 infection, Viral disease43.4% AI-predicted activityagainst E. coli50+ registered studies
- OmeprazoleExisting use: Duodenal ulcer, Dyspepsia, Esophagitis and 5 more43.3% AI-predicted activityagainst E. coli50+ registered studies
- Esomeprazole SodiumExisting use: Ankylosing spondylitis, Duodenal ulcer, Esophagitis and 5 more43.3% AI-predicted activityagainst E. coli46 registered studies
- Pasireotide PamoateExisting use: Acromegaly, Pituitary-dependent Cushing's disease43.3% AI-predicted activityagainst E. coli1 registered study
- EntecavirExisting use: Chronic hepatitis B virus infection, Hepatitis B virus infection, Liver disease and 1 more43.3% AI-predicted activityagainst E. coli50+ registered studies
- Azilsartan KamedoxomilExisting use: Hypertension, Stroke43.2% AI-predicted activityagainst E. coli1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications
NCT00645125 · start 2003-01
Registered record
- Registry ID
- NCT00645125
- Conditions
- Healthy
- Interventions
- cefdinir (Omnicef); amoxicillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-01
- Completion
- Not recorded
- Enrolment
- 154
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventioncefdinir (Omnicef); amoxicillinPhasePhase 4Registry statusCompletedSafety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media
NCT00645203 · start 2002-07
Registered record
- Registry ID
- NCT00645203
- Conditions
- Acute Otitis Media
- Interventions
- cefdinir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2002-07
- Completion
- Not recorded
- Enrolment
- 447
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Otitis MediaInterventioncefdinirPhasePhase 2 / Phase 3Registry statusCompleted